简介:AbstractBackground:Innovative coronavirus disease 2019 (COVID-19) vaccines, with elevated global manufacturing capacity, enhanced safety and efficacy, simplified dosing regimens, and distribution that is less cold chain-dependent, are still global imperatives for tackling the ongoing pandemic. A previous phase I trial indicated that the recombinant COVID-19 vaccine (V-01), which contains a fusion protein (IFN-PADRE-RBD-Fc dimer) as its antigen, is safe and well tolerated, capable of inducing rapid and robust immune responses, and warranted further testing in additional clinical trials. Herein, we aimed to assess the immunogenicity and safety of V-01, providing rationales of appropriate dose regimen for further efficacy study.Methods:A randomized, double-blind, placebo-controlled phase II clinical trial was initiated at the Gaozhou Municipal Centre for Disease Control and Prevention (Guangdong, China) in March 2021. Both younger (n = 440; 18-59 years of age) and older (n = 440; ≥60 years of age) adult participants in this trial were sequentially recruited into two distinct groups: two-dose regimen group in which participants were randomized either to follow a 10 or 25 μg of V-01 or placebo given intramuscularly 21 days apart (allocation ratio, 3:3:1, n = 120, 120, 40 for each regimen, respectively), or one-dose regimen groups in which participants were randomized either to receive a single injection of 50 μg of V-01 or placebo (allocation ratio, 3:1, n = 120, 40, respectively). The primary immunogenicity endpoints were the geometric mean titers of neutralizing antibodies against live severe acute respiratory syndrome coronavirus 2, and specific binding antibodies to the receptor binding domain (RBD). The primary safety endpoint evaluation was the frequencies and percentages of overall adverse events (AEs) within 30 days after full immunization.Results:V-01 provoked substantial immune responses in the two-dose group, achieving encouragingly high titers of neutralizing antibody and anti-RBD immunoglobulin, which peaked at day 35 (161.9 [95% confidence interval [CI]: 133.3-196.7] and 149.3 [95% CI: 123.9-179.9] in 10 and 25 μg V-01 group of younger adults, respectively; 111.6 [95%CI: 89.6-139.1] and 111.1 [95%CI: 89.2-138.4] in 10 and 25 μg V-01 group of older adults, respectively), and remained high at day 49 after a day-21 second dose; these levels significantly exceed those in convalescent serum from symptomatic COVID-19 patients (53.6, 95%CI: 31.3-91.7). Our preliminary data show that V-01 is safe and well tolerated, with reactogenicity predominantly being absent or mild in severity and only one vaccine-related grade 3 or worse AE being observed within 30 days. The older adult participants demonstrated a more favorable safety profile compared with those in the younger adult group: with AEs percentages of 19.2%, 25.8%, 17.5% in older adults vs. 34.2%, 23.3%, 26.7% in younger adults at the 10, 25 μg V-01 two-dose group, and 50 μg V-01 one-dose group, respectively.Conclusions:The vaccine candidate V-01 appears to be safe and immunogenic. The preliminary findings support the advancement of the two-dose, 10 μg V-01 regimen to a phase III trial for a large-scale population-based evaluation of safety and efficacy.Trial Registration:http://www.chictr.org.cn/index.aspx (No. ChiCTR2100045107, http://www.chictr.org.cn/showproj.aspx? proj=124702).
简介:摘要:本文规定了开关柜产品技术文件及工艺文件、产品图样中的零部件名称、定义及其编号,同时规定了开关电器设备产品零部件在企业信息管理系统中的编号原则。
简介:摘要:语文教材无非是例子,凭这个例子要学生能够举一反三,练成阅读和作文的熟练技能。老师教授这些例子,其实就是要做到教是为了不教。指导学生逐步掌握多种阅读方法,从而能够把握文章的主要内容。一、掌握借助关键语句理解一段话的意思的能力。二、提升把握课文主要内容的能力。
简介:摘要目的确认1例HLA-DQB1新等位基因的序列,分析新等位基因的遗传学特征。方法应用PCR-序列特异性寡核苷酸探针分型技术(sequence-specific oligonucleotide probe,SSOP)及PCR-直接测序分型法(sequence-based typing,SBT)对1个白血病家系进行HLA常规检测,发现患者母亲及哥哥HLA-DQB1序列组合无完全匹配的基因型。应用二代测序(next generation sequencing,NGS)技术对该基因进行确认。结果PCR-SBT提示患者母亲及哥哥HLA-DQB1序列组合与已知基因型不完全匹配。NGS分析显示,与同源性最高的等位基因DQB1*03:02相比,该等位基因在第2外显子c.233T>G变异,导致46位编码氨基酸由缬氨酸变为甘氨酸(p. Val46Gly)。家系调查显示患者哥哥HLA-DQB1新等位基因来源于母亲。新等位基因序列已递交给GenBank数据库(MK729743)。结论应用NGS鉴定了1个HLA-DQB1新等位基因,该等位基因被世界卫生组织HLA因子命名委员会正式命名为HLA-DQB1*03:362。
简介:摘要:鲁迅的散文和小说作品,蕴含着丰富的情感和深刻的思想,且语言文字具有独特的韵致,十分耐人咀嚼。鉴于学生在理解上存在一定难度,本文选取鲁迅的一些名篇,对文章的开头和结尾进行鉴赏,帮助读者深入鲁迅的情感世界,把握其高尚的人格与文学的风格。